Abstract | PURPOSE: METHODS: RESULTS:
Rapamycin treatment led to significant increases (P < 0.001) in dynamic glucose-enhanced signal in both the tumor and contralateral brain as compared to the no-treatment group, namely a maximum enhancement of 3.7% ± 2.3% ( tumor, treatment) versus 1.9% ± 0.4% ( tumor, no-treatment), 1.7% ± 1.1% (contralateral, treatment), and 1.0% ± 0.4% (contralateral, no treatment). Dynamic glucose-enhanced contrast remained consistently higher in treatment versus no-treatment groups for the duration of the experiment (17 min). This was confirmed with area-under-curve analysis. CONCLUSION:
|
Authors | Xiang Xu, Jiadi Xu, Linda Knutsson, Jing Liu, Huanling Liu, Yuguo Li, Bachchu Lal, John Laterra, Dmitri Artemov, Guanshu Liu, Peter C M van Zijl, Kannie W Y Chan |
Journal | Magnetic resonance in medicine
(Magn Reson Med)
Vol. 81
Issue 6
Pg. 3798-3807
(06 2019)
ISSN: 1522-2594 [Electronic] United States |
PMID | 30793789
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 International Society for Magnetic Resonance in Medicine. |
Chemical References |
- Antibiotics, Antineoplastic
- Sirolimus
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(pharmacology)
- Brain
(diagnostic imaging, drug effects)
- Brain Chemistry
(drug effects)
- Brain Neoplasms
(diagnostic imaging, metabolism)
- Cell Line, Tumor
- Female
- Glioblastoma
(diagnostic imaging, metabolism)
- Humans
- Magnetic Resonance Imaging
- Mice
- Mice, SCID
- Sirolimus
(pharmacology)
- Xenograft Model Antitumor Assays
|